Collectively, these data robustly implicate high PRMT3 expression as a pivotal PTM driving chemoradiation resistance in advanced colorectal cancer, associating it with inferior prognosis and attenuated responsiveness to neoadjuvant chemoradiation regimens. Here, PRMT3 is linked to colorectal cancer.